Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 27

1.

The clinical management of chronic myelomonocytic leukemia.

Padron E, Komrokji R, List AF.

Clin Adv Hematol Oncol. 2014 Mar;12(3):172-8.

PMID:
24927265
[PubMed - in process]
2.

Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML.

Lancet JE, Cortes JE, Hogge DE, Tallman MS, Kovacsovics TJ, Damon LE, Komrokji R, Solomon SR, Kolitz JE, Cooper M, Yeager AM, Louie AC, Feldman EJ.

Blood. 2014 May 22;123(21):3239-46. doi: 10.1182/blood-2013-12-540971. Epub 2014 Mar 31.

PMID:
24687088
[PubMed - in process]
3.

Pretransplantation 5-azacitidine in high-risk myelodysplastic syndrome.

Nishihori T, Perkins J, Mishra A, Komrokji R, Kim J, Kharfan-Dabaja MA, Perez L, Lancet J, Fernandez H, List A, Anasetti C, Field T.

Biol Blood Marrow Transplant. 2014 Jun;20(6):776-80. doi: 10.1016/j.bbmt.2014.02.008. Epub 2014 Feb 15.

PMID:
24534108
[PubMed - in process]
4.

Myelodysplastic syndromes: clinical practice guidelines in oncology.

Greenberg PL, Attar E, Bennett JM, Bloomfield CD, Borate U, De Castro CM, Deeg HJ, Frankfurt O, Gaensler K, Garcia-Manero G, Gore SD, Head D, Komrokji R, Maness LJ, Millenson M, O'Donnell MR, Shami PJ, Stein BL, Stone RM, Thompson JE, Westervelt P, Wheeler B, Shead DA, Naganuma M.

J Natl Compr Canc Netw. 2013 Jul;11(7):838-74.

PMID:
23847220
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study.

Foss FM, Sjak-Shie N, Goy A, Jacobsen E, Advani R, Smith MR, Komrokji R, Pendergrass K, Bolejack V.

Leuk Lymphoma. 2013 Jul;54(7):1373-9. doi: 10.3109/10428194.2012.742521. Epub 2013 Jan 29.

PMID:
23278639
[PubMed - indexed for MEDLINE]
6.

Assessing efficacy in myelofibrosis treatment: a focus on JAK inhibition.

Komrokji R, Verstovsek S.

Expert Rev Hematol. 2012 Dec;5(6):631-41. doi: 10.1586/ehm.12.50. Review.

PMID:
23216593
[PubMed - indexed for MEDLINE]
7.

Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison.

Phillips KM, Pinilla-Ibarz J, Sotomayor E, Lee MR, Jim HS, Small BJ, Sokol L, Lancet J, Tinsley S, Sweet K, Komrokji R, Jacobsen PB.

Support Care Cancer. 2013 Apr;21(4):1097-103. doi: 10.1007/s00520-012-1630-5. Epub 2012 Nov 20.

PMID:
23179489
[PubMed - indexed for MEDLINE]
8.

Naive T-cells in myelodysplastic syndrome display intrinsic human telomerase reverse transcriptase (hTERT) deficiency.

Yang L, Mailloux A, Rollison DE, Painter JS, Maciejewski J, Paquette RL, Loughran TP, McGraw K, Makishima H, Radhakrishnan R, Wei S, Ren X, Komrokji R, List AF, Epling-Burnette PK.

Leukemia. 2013 Apr;27(4):897-906. doi: 10.1038/leu.2012.300. Epub 2012 Oct 17.

PMID:
23072779
[PubMed - indexed for MEDLINE]
9.

Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes.

Sekeres MA, Tiu RV, Komrokji R, Lancet J, Advani AS, Afable M, Englehaupt R, Juersivich J, Cuthbertson D, Paleveda J, Tabarroki A, Visconte V, Makishima H, Jerez A, Paquette R, List AF, Maciejewski JP.

Blood. 2012 Dec 13;120(25):4945-51. doi: 10.1182/blood-2012-06-434639. Epub 2012 Aug 22.

PMID:
22915641
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion.

Wei S, Chen X, McGraw K, Zhang L, Komrokji R, Clark J, Caceres G, Billingsley D, Sokol L, Lancet J, Fortenbery N, Zhou J, Eksioglu EA, Sallman D, Wang H, Epling-Burnette PK, Djeu J, Sekeres M, Maciejewski JP, List A.

Oncogene. 2013 Feb 28;32(9):1110-20. doi: 10.1038/onc.2012.139. Epub 2012 Apr 23.

PMID:
22525275
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Immunomodulatory drugs and active immunotherapy for chronic lymphocytic leukemia.

Carballido E, Veliz M, Komrokji R, Pinilla-Ibarz J.

Cancer Control. 2012 Jan;19(1):54-67. Review.

PMID:
22143062
[PubMed - indexed for MEDLINE]
Free Article
12.

The 5q- syndrome: biology and treatment.

Padron E, Komrokji R, List AF.

Curr Treat Options Oncol. 2011 Dec;12(4):354-68. doi: 10.1007/s11864-011-0165-1.

PMID:
21964863
[PubMed - indexed for MEDLINE]
13.

Telomere length in myelodysplastic syndromes.

Rollison DE, Epling-Burnette PK, Park JY, Lee JH, Park H, Jonathan K, Cole AL, Painter JS, Guerrier M, Meléndez-Santiago J, Fulp W, Komrokji R, Lancet J, List AF.

Leuk Lymphoma. 2011 Aug;52(8):1528-36. doi: 10.3109/10428194.2011.568648. Epub 2011 Jun 3.

PMID:
21635204
[PubMed - indexed for MEDLINE]
14.

Biology and treatment of the 5q- syndrome.

Padron E, Komrokji R, List AF.

Expert Rev Hematol. 2011 Feb;4(1):61-9. doi: 10.1586/ehm.11.2. Review.

PMID:
21322779
[PubMed - indexed for MEDLINE]
15.

NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes.

Greenberg PL, Attar E, Bennett JM, Bloomfield CD, De Castro CM, Deeg HJ, Foran JM, Gaensler K, Garcia-Manero G, Gore SD, Head D, Komrokji R, Maness LJ, Millenson M, Nimer SD, O'Donnell MR, Schroeder MA, Shami PJ, Stone RM, Thompson JE, Westervelt P; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2011 Jan;9(1):30-56.

PMID:
21233243
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Uncommon of the uncommon: low-grade myelodysplastic syndrome evolving into chronic myelogenous leukemia.

Zhang L, Bennett JM, Zhang X, Moscinski L, Ibarz-Pinilla J, List AF, Komrokji R.

J Clin Oncol. 2011 May 20;29(15):e434-6. doi: 10.1200/JCO.2010.31.6265. Epub 2010 Dec 13. No abstract available.

PMID:
21149648
[PubMed - indexed for MEDLINE]
17.

The hematopoietic growth factors in the myelodysplastic syndromes.

Ortega J, Komrokji R, List AF.

Cancer Treat Res. 2011;157:363-82. doi: 10.1007/978-1-4419-7073-2_20. Review. No abstract available.

PMID:
21052966
[PubMed - indexed for MEDLINE]
18.

Decitabine versus 5-azacitidine for the treatment of myelodysplastic syndrome: adjusted indirect meta-analysis.

Kumar A, List AF, Hozo I, Komrokji R, Djulbegovic B.

Haematologica. 2010 Feb;95(2):340-2; author reply 343-4. doi: 10.3324/haematol.2009.017764. Epub 2009 Oct 22. No abstract available.

PMID:
19850902
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Phase II trial of thalidomide, irinotecan and gemcitabine in chemonaive patients with advanced non-small cell lung cancer.

Jazieh AR, Komrokji R, Gupta A, Patil S, Flora D, Knapp M, Issa M, Abdel Karim N.

Cancer Invest. 2009 Nov;27(9):932-6. doi: 10.3109/07357900801944856.

PMID:
19832041
[PubMed - indexed for MEDLINE]
20.

Outcome of esophageal carcinoma in the veteran affairs population: a comparative analysis from the Veteran Affairs Central Cancer Registry.

Beg MS, Navaneethan U, Atiq M, Komrokji R, Safa M.

Am J Clin Oncol. 2009 Jun;32(3):286-90. doi: 10.1097/COC.0b013e31818af0d8.

PMID:
19433959
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk